Vitro Announces Key Advance in Stem Cell Research

Vitro Diagnostics, Inc. (OTC BB:VODG.OB - News), dba Vitro Biopharma, announced the development of a new method to derive human pancreatic beta islets from adult pancreatic stem cells. Through research and development of stem cell differentiation methods, Vitro discovered a process that yields islets that appear structurally equivalent to those derived from the pancreas gland. These islets are produced in high yield and exhibit properties comparable to native islets including expression and secretion of biomarkers for insulin.

Dr. Jim Musick, Vitro's President and CEO, said, "The present advances in stem cell differentiation position the Company for additional commercial opportunities. We believe there is an unmet need for human beta islets in research and drug discovery applications. Our current efforts are directed towards further characterization of stem cell-derived beta islets produced by our newly discovered method and scale-up of production capacity to support anticipated initial commercial distribution."

There may also be therapeutic applications of stem cell technology in the treatment of diabetes. It has recently been shown that autologous bone marrow stem cell transplantation can slow the progression of early onset Type I diabetes probably by reducing autoimmune destruction of beta cells. A longer-term goal of the Company is to further develop its stem cell-derived beta islets for use in cell therapy of diabetes. The present advances may open opportunities to complete pre-clinical research studies and proceed with regulatory approval through the FDA, given the availability of adequate resources.

About Vitro Diagnostics, Inc.

Vitro Diagnostics, Inc. dba Vitro Biopharma (OTC BB:VODG.OB - News) http://www.vitrodiag.com, owns 29 patent-pending adult pancreatic stem cell lines that are distinct from the limited number of embryonic stem cell lines that are presently approved for federally funded research. These cell lines may have commercial application in diabetes research and therapy. The Company's reliance on adult stem cell lines obviates some ethical objections to embryonic stem cell research. Knowledge gained from its adult stem cell lines may also benefit studies of the differentiation of pleurapotent stem cell lines into human beta islets. The Company developed and manufactures the VITROCELL(TM) brand of human cell lines consisting of pituitary and pancreatic-derived cell lines and related products for various research and commercial applications.